Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gross Profit (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Gross Profit data on record, last reported at $6.5 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 141.05% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $14.4 million, up 57.23%, while the annual FY2025 figure was $14.4 million, 57.23% up from the prior year.
  • Gross Profit reached $6.5 million in Q4 2025 per LCTX's latest filing, up from $3.7 million in the prior quarter.
  • Across five years, Gross Profit topped out at $6.5 million in Q4 2025 and bottomed at $279000.0 in Q1 2021.
  • Average Gross Profit over 5 years is $2.5 million, with a median of $2.3 million recorded in 2023.
  • Peak YoY movement for Gross Profit: soared 1713.98% in 2022, then tumbled 58.45% in 2023.
  • A 5-year view of Gross Profit shows it stood at $1.3 million in 2021, then surged by 41.09% to $1.8 million in 2022, then increased by 1.05% to $1.8 million in 2023, then surged by 48.14% to $2.7 million in 2024, then surged by 141.05% to $6.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $6.5 million in Q4 2025, $3.7 million in Q3 2025, and $2.7 million in Q2 2025.